Signal #116625 · SEC 8-K

$KAPA SEC Filing Alert & Real-Time AI Stock Impact Analysis

Public T0 SEO entry. Full AI score & bullets unlock after 4 hours (VIP: instant).

FAQ: $KAPA filing catalyst

Why did $KAPA trigger an AI stock catalyst alert?

$KAPA triggered a Stock Catalyst AI alert on 2026-11-03 00:00:00 UTC for a SEC 8-K filing (AI Score: +6.5/10). Headline: Kairos Pharma Reports Phase 2 Interim Data with 17.7-Month PFS for ENV-105. Key points: - Interim Phase 2 analysis shows median PFS of 17.7 months for ENV-105 combination vs 2.0 months for apalutamide alone (P=0.0008) - Trial focuses on metastatic castration-resistant prostate cancer (mCRPC) - Presentation delivered at the Cancer R&D 2026 conference

How did $KAPA stock react after the SEC filing?

After the SEC 8-K for $KAPA, observed market reaction: T0 price $0.48. Past moves do not guarantee future results.

Where can I get real-time $KAPA SEC filing alerts?

Stock Catalyst AI pushes real-time SEC 8-K alerts for $KAPA via Telegram and the VIP Web Terminal from €10/month.

$KAPA

$KAPA – Kairos Pharma Reports Phase 2 Interim Data with 17.7-Month PFS for ENV-105

Kairos Pharma, LTD.

2026-11-03 00:00:00 UTC · SEC 8-K · All $KAPA

Unlocked archive · Analyzed in <2s at T0

Bullish AI Sentiment (+6.5 / 10)

Interim Phase 2 analysis shows median PFS of 17.7 months for ENV-105 combination vs 2.0 months for apalutamide alone (P=0.0008)
Trial focuses on metastatic castration-resistant prostate cancer (mCRPC)
Presentation delivered at the Cancer R&D 2026 conference

Unlock Live VIP Terminal & Telegram – €10/mo Original filing →